Submodule
Mechanistic Classes and Drug Access
Cholinomimetics either activate cholinoceptors directly or preserve endogenous acetylcholine by inhibiting its hydrolysis. Molecular charge and route strongly influence where each drug can act.
- Direct versus indirect action
- Muscarinic and nicotinic selectivity
- Reversible enzyme inhibition
- Quaternary versus tertiary access
Muscarinic, nicotinic, or both
Amplify endogenous ACh
Peripheral or central
Benefit and toxicity
Separate receptor agonism from enzyme inhibition
Direct agonists occupy muscarinic, nicotinic, or both receptor families. Cholinesterase inhibitors increase endogenous acetylcholine at every accessible cholinergic synapse where hydrolysis is inhibited. The second strategy can therefore amplify autonomic ganglia, parasympathetic effectors, sympathetic sweat glands, the neuromuscular junction, and the central nervous system according to drug distribution.
Use structure to predict distribution
Quaternary ammonium compounds remain permanently charged and cross lipid barriers poorly. Bethanechol, neostigmine, and pyridostigmine therefore have limited central access. Tertiary amines such as pilocarpine, physostigmine, donepezil, rivastigmine, and galantamine cross membranes more readily, although formulation and individual pharmacokinetics still matter.
Distinguish substrate-like resistance
Acetylcholine is rapidly hydrolyzed and activates muscarinic plus nicotinic receptors. Carbamate substitution can increase resistance to acetylcholinesterase, while beta-methyl substitution tends to increase muscarinic selectivity and reduce nicotinic activity. Bethanechol combines both features, producing a relatively muscarinic, hydrolysis-resistant profile.
Make route part of the mechanism
Inhaled methacholine is used as a controlled bronchial challenge, oral bethanechol targets bladder function systemically, oral pilocarpine or cevimeline stimulates secretion, and ophthalmic muscarinic agonists act locally but can still be absorbed. A mechanistic prediction is incomplete until concentration, formulation, route, and exposure are included.
Quick check
Submodule
Direct Muscarinic Agonists
Direct agonists differ in receptor selectivity, hydrolysis resistance, tissue access, and clinical purpose even though their adverse effects converge on excessive muscarinic signaling.
- Acetylcholine, methacholine, carbachol, and bethanechol
- Pilocarpine and cevimeline
- M2 cardiac and M3 smooth-muscle or gland effects
- Dose, route, and selectivity
Bladder and gastrointestinal smooth muscle
Glands, eye, systemic tissues
Salivary secretion
Controlled airway challenge
Predict the shared organ pattern
M3 signaling contracts detrusor, gastrointestinal, bronchial, iris sphincter, and ciliary smooth muscle and increases glandular secretion. M2 signaling slows sinoatrial firing and atrioventricular conduction. Endothelial M3 signaling can release nitric oxide and lower vascular tone when endothelium is intact.
Use choline esters selectively
Methacholine is used for inhaled bronchial challenge under controlled conditions. Bethanechol is labeled for acute postoperative or postpartum nonobstructive urinary retention and neurogenic bladder atony with retention. Mechanical obstruction must be excluded because stronger contraction against a closed outlet can cause harm.
Use alkaloid agonists for secretion
Oral pilocarpine is labeled for dry-mouth symptoms after head and neck radiotherapy and in Sjögren syndrome. Cevimeline is labeled for dry-mouth symptoms in Sjögren syndrome. Both can cause sweating, nausea, rhinitis, urinary frequency, visual effects, and cardiopulmonary changes. Uncontrolled asthma and situations in which miosis is undesirable are labeled contraindications.
Treat selectivity as relative
A drug described as muscarinic can still produce a broad muscarinic syndrome across organs. Dose escalation increases both intended and unintended receptor occupancy. Patient-specific reserve determines whether sweating is tolerable, bronchial secretion is dangerous, or a heart-rate change becomes clinically important.
Quick check
Submodule
Clinical Selection and Administration
Cholinergic therapy succeeds when indication, route, product instructions, functional outcome, and predictable organ-system toxicity are managed together.
- Nonobstructive urinary retention
- Xerostomia and salivary reserve
- Methacholine challenge
- Ophthalmic miosis and accommodation
No obstruction or unsafe reserve
Route and administration
Voiding, saliva, spirometry, vision
Continue, adjust, or stop
Administer bethanechol around meals
Current labeling recommends taking bethanechol one hour before or two hours after meals to reduce nausea and vomiting. Counsel about dizziness and orthostatic symptoms. Confirm that retention is functional rather than mechanical, and monitor voiding response, residual volume when appropriate, abdominal symptoms, heart rate, blood pressure, and bronchospasm.
Assess xerostomia functionally
Before a systemic secretagogue, review salivary reserve, hydration, oral disease, dental prevention, current medicines, asthma or chronic lung disease, cardiovascular history, and ocular contraindications. Monitor oral comfort, swallowing, sleep interruption, dental health, sweating, gastrointestinal effects, urinary frequency, and whether the patient experiences meaningful benefit.
Keep bronchial challenge controlled
Methacholine challenge uses escalating inhaled concentrations with spirometric monitoring and immediate access to bronchodilator rescue. It is a diagnostic procedure, not routine symptom therapy. Staff exposure, baseline lung function, medication withholding, contraindications, and stopping criteria follow the current product label and laboratory protocol.
Respect ophthalmic context
Muscarinic stimulation causes miosis and ciliary-muscle contraction. These effects can change aqueous outflow, accommodation, night vision, and retinal traction risk. Ocular pilocarpine products have indication-specific concentrations and instructions. Do not generalize one ophthalmic product's dose or indication to another.
Quick check
Submodule
Peripheral Cholinesterase Inhibitors
Neostigmine and pyridostigmine increase acetylcholine at peripheral muscarinic and nicotinic sites, making timing and paired safety measures as important as enzyme inhibition itself.
- Carbamate inhibition of acetylcholinesterase
- Myasthenia gravis symptom control
- Neuromuscular-block reversal
- Muscarinic protection and respiratory monitoring
Nicotinic + muscarinic sites
Transmission or block reversal
Pair protection when indicated
Not dose alone
Increase junctional acetylcholine
Pyridostigmine and neostigmine reversibly carbamylate acetylcholinesterase and slow acetylcholine hydrolysis. Their quaternary structures limit central penetration. At skeletal muscle, more acetylcholine can improve transmission in myasthenia gravis or compete with a nondepolarizing neuromuscular blocker.
Individualize myasthenia gravis timing
Pyridostigmine is used for symptomatic treatment of myasthenia gravis. Timing is often aligned with meals, activity, swallowing, and periods of greatest weakness. Monitor strength, bulbar and respiratory symptoms, diarrhea, cramping, salivation, sweating, bradycardia, and signs that excessive dosing may be worsening weakness.
Reverse only when recovery is sufficient
Current neostigmine injection labeling directs trained clinicians to use peripheral nerve stimulation and ensure ventilation and a patent airway until recovery. Dose depends on the depth and characteristics of nondepolarizing blockade. Giving a large dose when blockade is minimal can itself impair neuromuscular function.
Block the muscarinic burden
For reversal of nondepolarizing neuromuscular blockade, neostigmine is given with atropine or glycopyrrolate according to the label to reduce bradycardia and other muscarinic effects. The antimuscarinic does not replace objective confirmation of neuromuscular recovery or respiratory readiness.
Quick check
Submodule
Central Cholinesterase Inhibitors
Donepezil, rivastigmine, and galantamine provide symptomatic cholinergic therapy for selected dementias. Product, formulation, titration, tolerability, caregiver technique, and goals determine whether therapy remains useful.
- Donepezil, rivastigmine, and galantamine
- Labeled dementia indications
- Titration and interruption
- Gastrointestinal, cardiac, weight, and skin monitoring
Agent and formulation
Tolerability first
Pulse, weight, GI, skin
Goals and caregiver input
Set realistic treatment goals
Cholinesterase inhibitors do not restore lost neurons or cure dementia. They may provide symptomatic benefit or slow functional decline for some patients, while others experience little observable benefit or intolerable adverse effects. Reassess cognition, daily function, behavior, caregiver observations, adverse effects, and goals over time.
Match agent to labeled indication
Donepezil is labeled for dementia of the Alzheimer type across mild, moderate, and severe disease. Galantamine is labeled for mild to moderate Alzheimer dementia. Rivastigmine is labeled for Alzheimer dementia and mild to moderate dementia associated with Parkinson disease, with oral and transdermal formulations carrying product-specific instructions.
Titrate instead of rushing
Gradual titration reduces nausea, vomiting, diarrhea, anorexia, and weight loss. Donepezil 10 mg should not begin until 5 mg has been used for 4 to 6 weeks. The rivastigmine patch begins at 4.6 mg per 24 hours and increases only after at least 4 weeks at a tolerated dose. Galantamine extended release is taken in the morning, preferably with food, and requires renal and hepatic review.
Prevent formulation errors
Only one rivastigmine patch should be worn unless a specific label directs otherwise. Remove the old patch before applying the new one, rotate intact skin sites, avoid external heat, and inspect for reactions extending beyond the patch. After significant interruption, consult the current label because restarting at a lower dose may be required.
Quick check
Submodule
Safety, Interactions, and Cholinergic Excess
Cholinergic excess can combine secretory, gastrointestinal, pulmonary, cardiac, skeletal-muscle, and central findings. Airway and ventilation take priority over mnemonic recall.
- Muscarinic, nicotinic, and central manifestations
- Cholinergic versus myasthenic weakness
- Antimuscarinic and neuromuscular interactions
- Monitoring and emergency priorities
Secretions, gut, bladder, bradycardia
Fasciculation, weakness, paralysis
Confusion, seizure, coma
Stabilize before classification
Read the whole syndrome
Muscarinic excess produces salivation, lacrimation, sweating, bronchial secretions, bronchoconstriction, miosis, abdominal cramping, diarrhea, urination, bradycardia, and hypotension. Nicotinic excess can produce fasciculations followed by weakness or paralysis. Central exposure can cause confusion, seizures, or coma.
Protect ventilation first
Bronchorrhea, bronchospasm, central depression, and neuromuscular weakness can converge on respiratory failure. Immediate care focuses on airway control, suction, oxygenation, ventilation, decontamination when appropriate, and rapid expert consultation. Heart rate alone does not measure severity.
Distinguish weakness mechanisms
Worsening weakness in myasthenia gravis can reflect undertreatment, infection or another trigger, respiratory crisis, medication effect, or excessive cholinesterase inhibition. Muscarinic findings support cholinergic excess but may not always be prominent. Do not empirically escalate doses without assessing bulbar and respiratory function.
Audit interacting pharmacology
Anticholinergic medicines can oppose intended cholinergic therapy. Cholinesterase inhibitors can interact with succinylcholine and related neuromuscular agents, and bradycardia risk can increase with other rate-slowing drugs. Dementia labels also highlight gastrointestinal bleeding risk in susceptible patients and the need to monitor weight and hydration.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- DailyMed. Bethanechol chloride tablets
- DailyMed. Pilocarpine hydrochloride tablets
- DailyMed. Cevimeline capsules
- DailyMed. Neostigmine methylsulfate injection
- DailyMed. Pyridostigmine bromide tablets
- DailyMed. Donepezil hydrochloride tablets
- DailyMed. Rivastigmine transdermal system
- IUPHAR/BPS Guide to Pharmacology. Acetylcholine receptor families